| Medical Mutual | Kadcyla® (ado-trastuzumab emtansine) (Intravenous) | 2026-06-02 |
| Medical Mutual | Enhanced Oncology: Value (Intracochlear) | 2026-06-02 |
| UHC Medicare Advantage | Omnibus Codes – Medicare Advantage Medical Policy | 2026-06-01 |
| UHC UMR Medical and Drug | Ambulance Services – Commercial and Individual Exchange Medical Policy | 2026-06-01 |
| UHC UMR Medical and Drug | Breast Reduction Surgery – Commercial and Individual Exchange Medical Policy | 2026-06-01 |
| UHC UMR Medical and Drug | Catheter Ablation for Atrial Fibrillation – Commercial and Individual Exchange Medical Policy | 2026-06-01 |
| UHC UMR Medical and Drug | Chromosome Microarray Testing (Non-Oncology Conditions) – Commercial and Individual Exchange Medical Policy | 2026-06-01 |
| UHC UMR Medical and Drug | Cochlear Implants – Commercial and Individual Exchange Medical Policy | 2026-06-01 |
| UHC UMR Medical and Drug | Cosentyx® (Secukinumab) – Commercial Medical Benefit Drug Policy | 2026-06-01 |
| UHC UMR Medical and Drug | Cosmetic and Reconstructive Procedures – Commercial and Individual Exchange Medical Policy | 2026-06-01 |